These results are preliminary, observed in animal or cellular models. Research in humans is still limited.

Products containing CBG are not medicines and should not be used to diagnose, treat, or cure diseases.

Studies in rodent colitis models suggest that CBG can reduce intestinal inflammation, oxidative stress, and modulate immune responses.

In cell cultures, it has also been shown to reduce NF-κB pathway activation.

In vitro studies have shown that CBG can inhibit the growth of colon and melanoma cancer cells.

In animal models, a reduction in tumor progression was observed.

The results are preliminary.

CBG has been studied in preclinical models of neurodegenerative diseases, such as Huntington's.

The data point to a reduction in brain inflammation and increased neuronal viability under oxidative stress.

Studies with human keratinocytes and sebocytes suggest that CBG can regulate cell proliferation and control lipid production in the skin.

These are laboratory results, but they support the interest in topical applications.

In rodent studies, oral administration of CBG increased food intake without impairing locomotion.

This effect has sparked interest in studying conditions associated with appetite loss.